<DOC>
	<DOCNO>NCT00733785</DOCNO>
	<brief_summary>The present pharmacokinetic study design characterise pharmacokinetics RSG XR formulation aim assess dose proportionality , strength equivalence , food effect pharmacokinetics repeat dosing .</brief_summary>
	<brief_title>PK , Dose Proportionality , Food Effect And Repeat Dose Study Of Rosiglitazone XR In Healthy Volunteers</brief_title>
	<detailed_description>The present pharmacokinetic study design characterise pharmacokinetics RSG XR formulation manufacture Crawley aim assess dose proportionality , strength equivalence , food effect pharmacokinetics repeat dose . The study aim enroll sufficient number subject ensure 48 subject complete Study Part 1 ( 6 period crossover design ) 12 subject complete Study Part 2 ( repeat dose ) .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion apply : Healthy male female ( gender stratify ) subject age 1855 year inclusive healthy subject define individual free clinically significant illness disease determine medical history , physical examination , laboratory study , ECGs , test . A subject clinical abnormality laboratory parameter outside reference range age group may include Investigator GSK Medical Monitor consider finding introduce additional risk factor interfere study procedure . Body weight great 50 kg ( 110lbs Body mass index ( BMI ) 19 30 kg/m2 Willing able give write informed consent , willing participate full duration study , able understand follow instruction relate study procedure . Female subject able bear child must agree use adequate method contraception duration study 14 day last dose ( see detail highly effective method avoid pregnancy ) . Female subject premenopausal postmenopausal less 2 year must undertake pregnancy test ( serum test ) less equal 7 day Visit 1 , must negative Females , hormone replacement therapy ( HRT ) , whose menopausal status doubt , require use highly effective method avoid pregnancy , outline protocol , wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use highly effective method avoid pregnancy . A subject eligible inclusion study follow criterion apply : Any clinically relevant abnormality identify screen history physical laboratory examination medical condition circumstance make volunteer unsuitable participation study . Specific example include , coronary artery disease , myocardial infarction , congestive heart failure , type 2 diabetes , renal disease hypertension . If doubt appropriateness subject , subject 's eligibility study must review medical monitor prior enrolment . History surgical procedure might affect absorption rosiglitazone ( e.g. , partial/total gastrectomy , cholecystectomy ) hepatic biliary abnormality Gilbert 's syndrome . History regular alcohol consumption exceed 7 drinks/week female 14 drinks/week men ( 1 drink = 150mls wine 360mls beer 45mls hard liquor ) within 6 month screen . Subject smoke 10 cigarette per day . Positive urine drug screen ( UDS ) include alcohol screening checkin visit . Positive hepatitis B virus , hepatitis C virus HIV test screening . Positive serum betahuman chorionic gonadotropin test ( female ) . Women pregnant , lactating , plan become pregnant . Male subject willing abstain use condom sexual intercourse pregnant lactating female . Male subject willing use condom , plus another form contraception ( e.g. , spermicide , IUD , birth control pills take female partner , diaphragm spermicide ) engage sexual intercourse female could become pregnant . Male subject willing adhere contraceptive criterion administration study medication completion followup procedure . Female subject willing use propose contraceptive method . Use prescription nonprescription drug [ particular know inhibitor cytochrome 2C8 ( Gemfibrozil , trimethoprim , glitazone , monteleucast , quercetin ) inducer ( rifampin ) ] , vitamin , herbal dietary supplement ( include St. John 's Wort ) within 14 day 5 halflives ( whichever longer ) prior first dose study medication . Excluded list acetaminophen paracetamol dose less equal 2 grams/day , thyroid replacement therapy , hormonal method contraception ( include oral contraceptive , injectable progesterone , progestin subdermal implant progesteronereleasing IUDs , NOT postcoital contraceptive method ) hormone replacement therapy permit throughout study . Donation blood excess 500 mL within 56 day prior first dose study medication . History sensitivity heparin , heparininduced thrombocytopenia sensitivity study medication component thereof . History hypersensitivity rosiglitazone , excipients formulation . Systolic BP great 140 mm Hg and/or Diastolic BP great 90 mm Hg screening checkin . QTc ( machine read ) great 450 m screen ECG . History glucose intolerance ( serum glucose great 110 mg/dl 6.1 mmol/L 8 hour fast ) Subjects treatment new molecular entity ( investigational drug ) trial previous 30 day five halflives , whichever longer . ( washout last dose study medication previous study first dose study medication ) . Current evidence drug abuse history drug abuse within one year allocation Inability understand protocol requirement , instruction studyrelated restriction , nature , scope , possible consequence study Unlikely comply protocol requirement , instruction studyrelated restriction ; e.g. , uncooperative attitude , inability return followup visit , improbability complete study Subject investigator subinvestigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct study . Vulnerable subject ( e.g . person keep detention ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Rosiglitazone XR</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Strength Equivalence .</keyword>
	<keyword>Alzheimers Disease</keyword>
	<keyword>Repeat dose</keyword>
	<keyword>Dose proportionality</keyword>
</DOC>